Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Morning Wrap: Brent at $107, AI sell-off (15.09.2026)
Michael Burry’s portfolio: Revolution or rebalance?
US OPEN: AI slows, oil rises, markets fall
Market Wrap: European Stocks in the Red. AI Sinks, Oil Surges